TELA Bio (NASDAQ:TELA) Director Joseph Capper Buys 25,000 Shares of Stock

TELA Bio, Inc. (NASDAQ:TELA) Director Joseph Capper acquired 25,000 shares of TELA Bio stock in a transaction that occurred on Monday, September 14th. The stock was acquired at an average cost of $1.02 per share, for a total transaction of $25,500.00. Following the purchase, the director owned 54,827 shares of the company’s stock, valued at $55,923.54. The trade was a 83.82% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

TELA Bio Stock Performance

NASDAQ TELA opened at $1.18 on Thursday. The company has a market capitalization of $53.27 million, a price-to-earnings ratio of -1.53 and a beta of 1.36. TELA Bio, Inc. has a twelve month low of $0.50 and a twelve month high of $1.69. The stock has a fifty day simple moving average of $0.78 and a 200 day simple moving average of $0.79. The company has a quick ratio of 2.38, a current ratio of 2.99 and a debt-to-equity ratio of 8.82.

TELA Bio (NASDAQ:TELA) last announced its earnings results on Monday, August 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.03). The company had revenue of $19.29 million for the quarter, compared to the consensus estimate of $20.01 million. TELA Bio had a negative return on equity of 1,320.81% and a negative net margin of 51.53%. Sell-side analysts expect that TELA Bio, Inc. will post -0.76 EPS for the current year.

Institutional Investors Weigh In On TELA Bio

Several large investors have recently modified their holdings of the company. Nantahala Capital Management LLC bought a new position in TELA Bio during the second quarter worth $4,420,586. Stonepine Capital Management LLC bought a new stake in TELA Bio during the second quarter valued at $1,996,820. BlackRock Inc. bought a new stake in TELA Bio during the second quarter valued at $281,000. UP Strategic Wealth Investment Advisors LLC acquired a new stake in TELA Bio during the 2nd quarter worth about $91,000. Finally, Perkins Capital Management Inc. grew its holdings in TELA Bio by 1.5% during the 1st quarter. Perkins Capital Management Inc. now owns 1,418,328 shares of the company’s stock worth $879,000 after acquiring an additional 20,910 shares during the period. 94.35% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TELA Bio in a research note on Friday, July 17th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $2.20.

About TELA Bio

TELA Bio, Inc is a medical technology company focused on developing and commercializing implantable products for soft-tissue reconstruction. Its products are designed to support the repair and reinforcement of damaged or weakened soft tissue, including tissue affected by hernias, abdominal wall defects and other reconstructive procedures.

The company’s principal product platform is OviTex Reinforced Tissue Matrix, a family of biologic implants that combines extracellular matrix tissue with a polymer reinforcement structure.